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Introduction 
Diffuse malignant mesothelioma arises from the 
serous cavities, the most common site being the 
pleura. Although most researchers agree that there is 
a background incidence of malignant mesothelioma, 
the most significant aetiological agent is asbestos. 
The early diagnosis of mesothelioma is therefore 
important not only for medical but also for 
medicolegal reasons. 
Diffuse mesotheliomas are always malignant. They 
display a wide range of growth patterns, cellular 
composition and degree of cellular differentiation. 
They are classified by the World Health Organization 
as epithelial, mesenchymal or fibrous, and mixed. 
The various appearances of diffuse mesotheliomas 
have been well described (1). The epithelial form is 
predominant in most studies (2). Mixed tumours 
show both epithelial and mesenchymal features. The 
proportions between the two subtypes are usually 
unequal and the distribution is not uniform. 
The diagnosis of malignant mesothelioma is 
known to be difficult. Both adenocarcinomas of the 
pleura (metastases and peripheral lung cancers) and 
mesothelial hyperplasia often present considerable 
problems to the pathologist. 
Although it is still not uncommon for diagnosis to 
be made at autopsy (and not before), thoractomy and 
open biopsy are generally accepted as means of 
making a definitive diagnosis. Thoracoscopy is an 
attractive alternative to open surgery because of its 
low complication rate and the possibility to obtain 
material from several selected areas, permitting 
staging. Accuracy rates close to 100% have been 
reported (3,4). The value of closed needle biopsy in 
the diagnosis is questioned. A success rate of 60% 
was claimed by Edge and Choudhury (5), but lower 
figures are usually reported (l&S). 
Effusion of the serous cavities is the most common 
mode of presentation of malignant mesothelioma. It 
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is seen in all types of malignant mesotheliomas, but 
only tumours with an epithelial component are prone 
to shed potentially diagnostic cells into the effusion. 
The diagnostic accuracy of smears from effusions 
varies considerably and the figures are difficult to 
compare (2,9-15). A study from the 1970s reports an 
accuracy rate of 4% (16), and low figures are also 
reported in a more recent study (17). Whitaker and 
Shilkin (8) report a sensitivity of 62%, but give no 
specificity figure. A similar figure is reported by Di 
Bonito et al. (18). 
In recent studies, statistical methods have been 
used to identify criteria that differentiate mesothe- 
lioma from other conditions (19). Today a number 
of ancillary techniques are available in addition to 
conventional morphology, and are recommended 
to improve the diagnostic accuracy of mesothelioma. 
Electron Microscopy 
Ultrastructural examination has been performed 
on both histological material (1) and cells obtained 
from effusions (6,20-22). When trying to arrive at a 
diagnosis on the basis of minimal material, the single 
most rewarding type of specimen seems to be the cell 
pellet from an effusion (8). The TEM appearances of 
malignant mesothelioma are well-documented. Long 
slender complex microvilli, cytoplasmic filaments, 
intracytoplasmic neolumina with microvilli, apical 
tight junctions, well-developed, elongated desmo- 
somes and abundant glycogen are characteristic 
features (23,24). The triad of microvilli, intermediate 
filaments and intracytoplasmic neolumina has been 
described as typical of mesothelioma (23) but was 
observed in only half of the 10 cases studied by 
Warhol et al. (20) and it has also been observed in 
adenocarcinomas. These authors found the length/ 
diameter ratio of the microvilli a particularly useful 
parameter in distinguishing mesothelioma from 
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adenocarcinoma. Abundant intermediate filaments 
was also useful for defining a mesothelioma (20). 
Burns et al. found that measurement of the 10 longest 
microvilli alone was sufficient for a reasonably good 
diagnostic discrimination between mesothelioma and 
adenocarcinoma (25). 
Presence of secretory vacuoles, marked aggre- 
gations of microfilaments with desmosomal involve- 
ment, and microvilli with core rootlet formation, 
glycocalyx and a prominent basement membrane are 
findings indicating an adenocarcinoma (26). The 
microvilli found in adenocarcinomas are shorter, 
less in number, and more club-like than those in 
mesotheliomas (20). 
It is often claimed that there is no ultrastructural 
difference between neoplastic and benign mesothelial 
cells. However, it has been reported that benign 
mesothelial cells have shorter surface microvilli 
instead of the long, complex, branching microvilli 
seen in mesothelioma cells (27). This is in accordance 
with the, author’s own experience. Other features of 
malignancy are intrastromal projection of microvilli 
from the basolateral surface of mesothelial cells (28), 
and the apparent incorporation (due to cross-cutting) 
of membrane-related collagen fibres in the cells (29). 
Histochemical Staining 
In spite of their often epithelial morphology, meso- 
theliomas must be biologically considered sarcomas. 
They may reveal their sarcomatous nature by pro- 
ducing mesenchymal matrix substances, such as 
hyaluronan, a glycosaminoglycan (GAG). Cationic 
dyes, such as Alcian blue, can be used to demonstrate 
GAGS histolochemically in tissue sections (30). If the 
staining is performed before and after digestion with 
a specific hyaluronidase, hyaluronan can be demon- 
strated (3 1,32). However, Alcian blue positivity is not 
a constant feature of mesotheliomas (12,33). Since 
hyaluronan is water-soluble, it can be extracted by 
aqueous solutions, such as formalin, and during 
staining with an aqueous media. Another problem 
is that tissue proteins may interfere with the effect 
of pH on Alcian blue staining (34). Further- 
more, Alcian blue positivity is found in some 
adenocarcinomas (29). 
Adenocarcinomas are more likely to secrete 
mucins with neutral or acid oligosaccharides that can 
be demonstrated with the periodic acid-Schiff (PAS) 
staining. However, many mesothelioma cells contain 
abundant amounts of glycogen, which also stains 
with PAS (8,35). PAS-staining must therefore be 
performed after digestion with diastase (36). How- 
ever, only half, or less, of the adenocarcinomas are 
mucin-positive (12,33,37). The mucicarmine stain is 
relatively specific for the demonstration of acid 
mucipolysaccharides of epithelial origin but meso- 
theliomas may also show reactivity (1). Therefore, 
these stains leave most cases unresolved and some 
laboratories have replaced histochemical tests by 
immunocytochemistry (8). 
Immnnocytochemistry 
Many immunocytochemical studies using various 
antibodies have been performed on mesothelioma 
material during recent years. The main aim has been 
to distinguish mesothelioma from adenocarcinoma, 
and the basic assumption has been that meso- 
theliomas, being of mesenchymal origin, may have 
an immunophenotype different from that of 
adenocarcinomas. 
CAR~IN~EMBRY~NI~ ANTIGEN (CEA) 
In 1979, Wang et al. (38) found that CEA was not 
expressed in mesotheliomas, but was present in 
adenocarcinomas. These findings were later con- 
firmed by others (24,394l) and CEA has become the 
most widely used marker for distinguishing between 
mesothelioma and adenocarcinoma. However, 
early warnings were given that unequivocal CEA- 
reactivity may exist in mesotheliomas (4248). CEA 
reactivity in mesotheliomas has been attributed 
to cross-reacting substances, mainly non-specific 
cross-reacting antigen (NCA). Absorption with 
spleen powder removes reactivity due to NCA, 
but also diminishes the proportion of reactive 
adenocarcinomas (49). 
When monoclonal anti-CEA-antibodies became 
available, a higher specificity was presumed. How- 
ever, some monoclonal antibodies showed reactivity 
to mesothelioma (46), while others did not (5e-53). 
In a comparison of five commercially available 
monoclonal CEA-antibodies, the author found that 
only the preparation from Dakopatts was sufficiently 
specific. Results indicated that CEA reactivity in 
mesotheliomas is due to the presence of substances 
sharing epitopes with CEA but not to the presence of 
the entire CEA molecule (54). 
INTERMEDIATE FILAMENTS 
The expression of intermediate filaments in 
mesothelial cells and mesotheliomas has received 
much attention. Normal surface mesothelial cells 
express cytokeratin, whereas ‘dormant’ subserosal 
cells express vimentin. Proliferating subserosal cells 
express both vimentin and keratins of lower molecu- 
lar weight. The co-expression of keratin and vimentin 
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appears to be restricted to the subserosal cells, and 
Bolen et al. refer to these cells as ‘multi-potential 
subserosal cells’ (MSCs) (24). When the cells differ- 
entiate into surface mesothelial cells, they acquire 
keratins of higher molecular weight, but eventually 
they lose vimentin. Epithelial mesothelioma cells 
resemble non-neoplastic surface mesothelium, 
expressing the full spectrum of keratins but often 
lacking vimentin, whereas fibrous mesothelioma 
cells co-express low molecular weight keratins and 
vimentin (23,24). 
Keratins of lower molecular weight are found 
both in adenocarcinomas and mesotheliomas 
(24,45,49,51,55,56), whereas epithelial mesothelio- 
mas also express keratins of high molecular weight 
(55-60). Expression of keratins, especially stratified 
keratins, is less common or may be absent in sarco- 
matous tumour cells (43,61). Thus, neoplastic meso- 
thelium resembles its reactive counterpart in this 
respect (24). 
Co-expression of keratin and vimentin was previ- 
ously thought to be specific for mesotheliomas 
but it can also be seen in tumours of epithelial 
origin, such as pulmonary carcinomas (62,63), 
breast cancers (64) and endometrial carcinomas 
(65). Moreover, various carcinomas co-express 
keratin and vimentin when growing in effusions of 
the body cavities (66). The value of co-expression 
of intermediate filaments for distinguishing be- 
tween adenocarcinoma and mesothelioma is also 
reduced by the fact that the epithelial component 
mesotheliomas 
;;4,5 1,67). 
is often vimentin-negative 
Leiomyomatous differentiation in mesotheliomas 
is well known. The reactivity to antibodies against 
desmin in various tissues has been studied but further 
investigations are needed to assess the utility of 
desmin in the diagnosis of mesothelioma (68). 
EPITHELIAL MEMBRANE ANTIGEN (EMA) 
This antigen was first demonstrated with antisera 
raised against defatted human cream. It is closely 
related to HMFG-2 (human milk fat globule) (69). 
Several studies have shown that EMA-reactivity, 
as such, is of little value in the differentiation 
between adenocarcinoma and mesothehoma 
(39,41,44,47,50,51,70). However, a specific staining 
pattern with predominant membrane staining has 
often been observed in mesotheliomas, whereas the 
staining in adenocarcinomas is more often concen- 
trated in the cytoplasm. This observation was made 
in material from effusions by Van der Kwast et al. 
(71) and later by others, both in cytological and 
histological specimens (72). 
EMA and HMFG reactivity in non-neoplastic 
mesothelial cells is controversial. It was absent or 
infrequent in some studies on cytological specimens 
(73-76). Ghosh et al. found strong HMFG reactivity 
in 30% of benign effusions (77); and in a study by To 
et al., 25 of 127 benign effusions stained with EMA 
(only weakly, in most cases) (78). 
LEUMl I 
LeuMl, a monocyte-granulocyte-related marker 
expressed by Reed-Sternberg cells in Hodgkin’s dis- 
ease, was shown by Sheibani et al. to react with most 
adenocarcinomas, but not with mesotheliomas or 
most other sarcomas. Their results were later con- 
firmed (41,79). Some investigators have found reac- 
tivity in a small proportion of the mesotheliomas 
tested (80). 
B12.3 
This monoclonal antibody was raised against cell 
membranes derived from human breast cancer cells 
(TAG-72). It is often reactive in adenocarcinomas 
but not in mesotheliomas (46,51,81). Reactivity in 
mesotheliomas has occasionally been described, how- 
ever, and the proportion of positive adenocarcinomas 
varies considerably. 
BEREP 
BerEp is a fairly recently developed monoclonal 
antibody (82). When applied to formalin-fixed, 
paraffin-embedded tissue, it stained most adenocarci- 
nomas but only one of 115 mesotheliomas tested (83). 
Later studies on both cytological and histological 
specimens have, however, revealed reactivity in some 
mesotheliomas (84-87). 
EXTRACELLULAR MATRIX PROTEINS 
Collagen is the major protein in the extracellular 
matrix. Types I, II and III are the fibrillar collagens, 
while type IV forms the core of all basal laminae. 
Collagen type I indicates a mesenchymal origin, and 
collagen type IV is found in the basement membranes 
of epithelial tissues. One immunocytochemical study 
revealed collagen types I and IV in mesothelioma cell 
lines and in normal pleura, while lung carcinoma cells 
contained only collagen type IV (88). Reactivity in 
mesotheliomas to antibodies against type IV collagen 
and to laminin has also been demonstrated by 
others, and it can be concluded that mesotheliomas 
are capable of synthesizing basement membrane 
substances (89). 
OTHER ANTIBODIES 
Many other antibodies have been tested for the 
purpose of distinguishing between adenocarcinoma 
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Table I Immunocytochemical reactivity in mesotheliomas and adenocarcinomas 
Antibody Labels Author 
Cal-antibody 
SPl 
Cal9-9 
AUA 1 
CAKl 
SC 
PL 
NSE 
Leu I 
SlOO 
a-1-antichymotrypsin 
Anti-mesothel 
antibodies 
Anti-human 
thrombomodulin 
ME1 
DF3 
OV 632 
BMA-120 
Adenoca 
Some mesotheliomas 
Adenoca 
Adenoca 
Adenoca 
Mesothelioma 
Adenoca 
Adenoca, mesothelioma 
Adenoca, mesothelioma 
Mesothelioma 
Mesothelioma 
Adenoca, mesothelioma 
Adenoca, mesothelioma 
Mesothelial cells 
Mesothelioma 
Mesothelioma, 
Some adenoca 
Adenoca, mesothelioma 
Ovarian cancer mesothelioma 
Mesothelioma 
Ashall et al. (90), McGee et al. (91), 
Woods et al. (92) 
Burnett et al. (93), 
Pallesen et al. (94) 
Gibbs et al. (95), Pfaltz et al. (47), 
Ordonez (51) 
Ordonez (5 1) 
Spurr et al. (96), Soosay et al. (53) 
Chang et al. (97) 
Kondi-Paphitis and Addis (98), 
Ordonez (51) 
Loosli and Hurlimann (44) 
Gibbs et al. (95), Ordonez (51) 
Maya11 et al. (99) 
Maya11 ef al. (99) 
Rasmussen and Larsen (loo), 
Pfaltz et al. (47), Ordonez (51) 
Herbert and Gallagher, (101) 
Permatter and Wiesinger (102) 
Singh et al. (103), 
Donna et ul. (104106) 
Donna et al. (107) (cyt) 
Collins et al. (108) 
O’Hara et al. (109) 
Skov et al. (110) 
Szpak et al. (111) (cyt) 
Van der Kwast et al. (112) (cyt) 
Guzman et al. (113) (cyt) 
NSE, neuron-specific enolase; PL, human placental antigen; SPl bl, pregnancy-specific 
glycoprotein; SC, secretory component. 
and mesothelioma. Some of these are given in 
Table 1. Most of them have been assumed to be 
reactive with adenocarcinomas, but not with meso- 
theliomas. Usually the number of tested cases 
has been small and many antibodies have been 
investigated by only a few authors. 
ANTIBODY PANELS 
Since no single antibody differentiates between 
adenocarcinoma and mesothelioma, batteries of anti- 
bodies are usually recommended for the purpose. 
In a few recent investigations, statistical methods 
have been used to optimize batteries of antibodies. 
By means of stepwise logistic regression analysis, 
Frisman et al. found that a panel consisting of 
anti-CEA, anti-EMA and B72.3 for distinguishing 
between adenocarcinoma and all kinds of mesothelial 
proliferations resolved over 95% of the cases. Only 
EMA was selected by the statistical analysis to dis- 
tinguish between benign and neoplastic mesothelial 
cells (114). In the author’s own study, comprising 
103 mesotheliomas and 43 adenocarcinomas, step- 
wise logistic regression selected five parameters of 
major importance: vimentin reactivity in epithelial 
cells; CAM 5.2 reactivity in fibroblast-like cells; 
membrane-bound EMA reactivity; lack of reactivity 
to Leu Ml; and BerEp (115). 
Analysis of Hyaluronan in Effusions and 
Tissue Extracts 
The hyaluronan produced in excess amounts in 
some mesotheliomas can be identified in the effusions 
frequently caused by the tumour. Various techniques 
with different specificities and sensitivities can be 
used to demonstrate hyaluronan. Waxler et al. used 
electrophoresis of papain digests of tissue from meso- 
theliomas and from other tumours. They found that 
practically all the demonstrable GAGS in the meso- 
theliomas were hyaluronan, whereas the control 
tumours also contained other GAGS (166). A modi- 
fication of the method was used by Chiu et al., who 
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found larger amounts of hyaluronan in meso- 
theliomas, soft tissue sarcomas and ovarian serous 
carcinomas than in adenocarcinomas of the lung 
(117). The results obtained with an electrophoretic 
method for the analysis of effusions indicated that 
among fluids with hyaluronan values above 50 mg 
1 - ‘, 82% were due to a mesothelioma (118). A 
radioassay method with hyaluronan-binding protein 
was tested by Pettersson et al. who found high values 
in most mesothelioma fluids, but not in effusions 
produced by other tumours. However, a considerable 
number of effusions from non-malignant diseases 
also showed elevated levels (119), as later confirmed 
by others (120,121). Martensson et al. compared 
three methods (122): a viscosimetric method 
described by Sundblad (123); the indirect radioassay 
method, initially described by Tengblad (124), and 
Laurent and Tengblad (125), and further developed 
as a commercial kit (126); and a high-performance 
liquid chromatography (HPLC) method developed 
by Hjerpe et al. (127,128). The latter two methods 
were sensitive enough for use in the diagnosis of 
mesothelioma. With the HPLC method, a value 
of 75 mg 1 - ’ was found to be 100% specific for 
mesothelioma (129). 
Closing Remarks 
An accurate diagnosis of mesothelioma at an early 
stage of disease is important, especially since new, 
more promising therapeutical modalities are emerg- 
ing. With a multimodal approach including the use 
of ancillary techniques, it is possible to arrive at a 
correct morphological diagnosis, based on a small 
amount of tissue, in a considerable number of 
cases. 
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